1. Home
  2. BATRA vs ACAD Comparison

BATRA vs ACAD Comparison

Compare BATRA & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Atlanta Braves Holdings Inc. Series A

BATRA

Atlanta Braves Holdings Inc. Series A

N/A

Current Price

$53.53

Market Cap

3.5B

Sector

Industrials

ML Signal

N/A

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

N/A

Current Price

$21.70

Market Cap

3.8B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BATRA
ACAD
Founded
1991
1993
Country
United States
United States
Employees
1610
N/A
Industry
Broadcasting
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.5B
3.8B
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
BATRA
ACAD
Price
$53.53
$21.70
Analyst Decision
Buy
Buy
Analyst Count
2
22
Target Price
$60.00
$30.55
AVG Volume (30 Days)
36.4K
1.3M
Earning Date
05-11-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
69.12
EPS
N/A
0.02
Revenue
N/A
$726,437,000.00
Revenue This Year
$12.40
$18.80
Revenue Next Year
$8.54
$11.70
P/E Ratio
N/A
$1,078.00
Revenue Growth
N/A
40.45
52 Week Low
$41.50
$19.69
52 Week High
$56.06
$28.35

Technical Indicators

Market Signals
Indicator
BATRA
ACAD
Relative Strength Index (RSI) 52.03 48.50
Support Level $52.83 $21.12
Resistance Level $54.58 $22.03
Average True Range (ATR) 0.90 0.59
MACD -0.16 0.05
Stochastic Oscillator 52.92 68.07

Price Performance

Historical Comparison
BATRA
ACAD

About BATRA Atlanta Braves Holdings Inc. Series A

Atlanta Braves Holdings Inc is a holding company. It operates through its wholly-owned subsidiary, which is the owner and operator of the Atlanta Braves Major League Baseball Club and the mixed-use real estate development, The Battery Atlanta, and is the operator of the Atlanta Braves Major League Baseball Club's stadium, Truist Park. The company predominantly derives revenue related to the Braves baseball franchise and Truist Park from ticket sales, concessions, local broadcasting rights, advertising sponsorships, suites and premium seat fees, retail and licensing revenue, shared MLB revenue streams, including national broadcasting rights and licensing, and other sources. The company's reportable segments include: Baseball which generates key revenue, and Mixed-Use Development.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Share on Social Networks: